HSK31858 not checked
Haisco Pharmaceutical Group Co., Ltd. · CHF10196
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 52-week treatment period in patients with non-cystic fibrosis bronchiectasis”In the company’s words, NCT06660992 on ClinicalTrials.gov
- Tested for
- Non-cystic Fibrosis Bronchiectasis (NCFBE) (3 trials), Non-cystic Fibrosis Bronchiectasis (2 trials), Bronchiectasis (2 trials), Asthma Bronchiale, Chronic Obstructive Pulmonary Disease (COPD)
- Main trialPhase 3
- “This is a phase III, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in non-cystic fibrosis bronchiectasis (NCFBE) participants.”In the company’s words, NCT06660992 on ClinicalTrials.gov
- Other names
- CHF10196
Other drugs for Non-cystic Fibrosis Bronchiectasis (NCFBE)
- VerducatibBoehringer Ingelheim · Phase 3
- GSK3862995BGSK · Phase 2
- CTX-187Centauri Therapeutics Limited · Phase 1
Coming up9
- 28 NovPhase 3 trial completes · ClinicalTrials.gov
- 30 NovPhase 1 trial completes · ClinicalTrials.gov
- NovPhase 1 trial completes · ClinicalTrials.gov
- NovPhase 1 trial completes · ClinicalTrials.gov
- 9 DecPhase 1 trial completes · ClinicalTrials.gov
- DecPhase 1 trial completes · ClinicalTrials.gov
- 15 Dec 2028Phase 1 trial completes · ClinicalTrials.gov
- 10 Jan 2029Phase 3 trial completes · ClinicalTrials.gov
- Apr 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials16
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 28 Nov 2026 | A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis | |
| Phase 3Recruiting | 10 Jan 2029 | A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis | |
| Phase 3Not yet recruiting | Apr 2030 | A Study to Evaluate the Efficacy and Safety of CHF10196 Tablets (Florensocatib) Compared With Placebo in Male and Female Participants 12 to 85 Years of Age With Bronchiectasis | |
| Phase 2Enrolling by invitation | 23 Apr 2026 | A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion | |
| Phase 1Active, not recruiting | 24 Dec 2024 | Clinical Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of HSK31858 in Healthy Subjects | |
| Phase 1Enrolling by invitation | 30 Nov 2026 | Clinical Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HSK31858 in Healthy Subjects | |
| Phase 1Recruiting | Nov 2026 | Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Renal Impairment | |
| Phase 1Recruiting | Nov 2026 | Phase 1 Study to Assess the Effects of HSK31858 on the QT/QTc Interval in Healthy Chinese Participants | |
| Phase 1Not yet recruiting | 9 Dec 2026 | A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male Participants | |
| Phase 1Recruiting | Dec 2026 | Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Hepatic Impairment | |
| Phase 1Not yet recruiting | 15 Dec 2028 | A Study in Healthy Male Participants to Compare How CHF10196 Affects How the Body Absorbs and Processes Two Commonly Used Medicines: Dabigatran, a Blood Thinner, and Rosuvastatin, a Medicine Used to Lower Cholesterol | |
| Phase 2Completed | 29 Mar 2024 | A Study of HSK31858 in Participants with Non-Cystic Fibrosis Bronchiectasis | |
| Phase 2Unknown | 22 Mar 2026 | A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma | |
| Phase 1Completed | 19 Apr 2022 | A Study of Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosed of HSK31858 in Healthy Volunteers | |
| Phase 1Completed | 15 Aug 2022 | Safety, Tolerability,PK/PD, Food Effect of Single and Multiple Ascending Doses of HSK31858 in Healthy Volunteers | |
| Phase 1Unknown | 2 Jul 2024 | Mass Balance Study of [14C]HSK31858 in Healthy Adult Male Chinese Subjects. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026